Using patent data to assess the value of pharmaceutical innovation

Journal of Law, Medicine and Ethics

Volumn 37, Issue 2, 2009, Pages 176-183

  Kesselheim, Aaron S ^a,b   Avorn, Jerry ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67650239749     PISSN: 10731105     EISSN: 1748720X     Source Type: Journal    
DOI: 10.1111/j.1748-720X.2009.00364.x     Document Type: Article

References (32)

1. J. Blum FDA Approves 19 new U.S. drugs, Fewest Since '83; Glaxo Leads Bloomberg News, January 8, 2008, available at http://www.bloomberg.com/apps/ news?pid=newsarchive&sid=a2MOCNVDHucs (last visited March 25, 2009).
2. S. Keyhani, M. Diener-West, and N. Powe Are Development Times for Pharmaceuticals Increasing or Decreasing Health Affairs 25, no. 2 (2006 461 468.
3. Government Accountability Office, Science, Business, Regulatory and Intellectual Property Issues Cited as Hampering Drug Development Efforts, November 2006, available at http://oversight.house.gov/Documents/20061219094529- 73424.pdf (last visited March 25, 2009).
4. A. F. Holmer, Testimony by President and CEO of Pharmaceutical Research and Manufacturers of America on "Prescription Drug Safety and Pricing" before the Senate Committee on Health, Education, Labor, and Pensions, June 13, 2000, Congressional Record, 146, no. 73. (2000).
5. Pharmaceutical Research and Manufacturers of America, Foreign Government Pharmaceutical Price and Access Controls, July 1, 2004, available at http://www.ita.doc.gov/td/health/phRMA/phRMA%20Response.pdf (last visited March 25, 2009).
6. M. A. Gagnon and J. Lexchin The Cost of Pushing Pills: A New Estimate of Pharmaceutical Promotion Expenditures in the United States PLoS Medicine 5, no. 1 (2008 e1.
7. J. Avorn, Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs (New York : Alfred A. Knopf, 2005).
8. R. Tamblyn, R. Laprise, and J. A. Hanley, et al. Adverse Events Associated with Prescription Drug Cost-sharing Among Poor and Elderly Persons JAMA 285, no. 4 (2001 421 429 M. A. Steinman, L. P. Sands, K. E. Covinsky, "Self-Restriction of Medications Due to Cost in Seniors Without Prescription Coverage," Journal of General Internal Medicine 16, no. 12 (2001): 793-799. (Pubitemid 32097260)
9. Z. Griliches, ed., R&D, Patents, and Productivity (Chicago : University of Chicago Press, 1985).
10. M. Trajtenberg A Penny for your Quotes: Patent Citations and the Value of Innovations RAND Journal of Economics 23, no. 1 (1990 172 187.
11. R. Henderson, A. B. Jaffe, and M. Trajtenberg Universities as a Source of Commercial Technology: A Detailed Analysis of University Patenting, 1965-1988 The Review of Economics and Statistics 80, no. 1 (1998 119 127 A. B. Jaffe, M. S. Fogarty, and B. A. Banks. "Evidence from Patents and Patent Citations on the Impact of NASA and Other Federal Labs on Commercial Innovation," Journal of Industrial Economics 46, no. 2 (1998): 183-199; D. Mowery, B. Sampat, and A. Zeidonis, "Learning to Patent: Institutional Experience, Learning, and the Characteristics of U.S. University Patents after the Bayh-Dole Act, 1981-1992, Management Science 48, no. 1 (2002): 73-89.
12. S. Shane Technological Opportunities and New Firm Creation Management Science 47, no. 2 (2001 205 220. (Pubitemid 34192759)
13. D. Harhoff, F. Narin, F.M. Scherer, and K. Vopel Citation Frequency and the Value of Patented Inventions The Review of Economics and Statistics 81, no. 3 (1999 511 515 A. B. Jaffe, M. Trajtenberg, and M. S. Fogarty, "Knowledge Spillovers and Patent Citations: Evidence from a Survey of Inventors," AEA Papers and Proceedings 90, no. 2 (2000): 215-218.
14. J. O. Lanjouw and M. Schankerman Patent Quality and Research Productivity: Measuring Innovation with Multiple Indicators The Economic Journal 114, no. 495 (2004 441 465. (Pubitemid 38516955)
15. E. Sapsalis, B. van Pottelsberghe de la Potterie, and R. Navon Academic Versus Industry Patenting: An In-Depth Analysis of What Determines Patent Value Research Policy 35, no. 10 (2006 1631 1645. (Pubitemid 44792245)
16. National Bureau of Economic Research, The NBER US Patent Citations Data File, available at http://www.nber.org/patents (last visited March 27, 2009).
17. B. H. Hall, A. B. Jaffe, and M. Trajtenberg The NBER Patent Citations Data File: Lessons, Insights, and Methodological Tools NBER Working paper 8498, October 2001, available at http://www.nber.org/papers/w8498.pdf (last visited April 10, 2009).
18. B. H. Hall, A. B. Jaffe, and M. Trajtenberg Market Value and Patent Citations: A First Look Institute of Business and Economic Research, Paper E00'277 (May 2000), available at http://repositories.cdlib.org/cgi/viewcontent. cgi?article=1036&context=iber/econ# (last visited March 27, 2009).
19. United States Patent and Trademark Office, Classification Definitions, January 2005, available at http://www.uspto.gov/go/classification/uspc424/ defs424.htm) (last visited March 27, 2009).
20. M. Trajtenberg, R. Henderson, and A. Jaffe University Versus Corporate Patents: A Window on the Basicness of Invention Economics of Innovation and New Technology 5, no. 1 (1997 19 50.
21. National Science Foundation U.S. Industrial R&D Performers Report Increased Expenditures for 2004 December 2006, available at http://www.nsf.gov/ statistics/infbrief/nsf07304/nsf07304.pdf (last visited March 27, 2009).
22. J. Loscalzo The NIH Budget and the Future of Biomedical Research New England Journal of Medicine 354, no. 16 (2006 1665 1667.
23. A. B. Jaffe and M. Trajtenberg Flows of Knowledge from Universities and Federal Laboratories: Modeling the Flow of Patent Citations over Time and Across Institutional and Geographic Boundaries Proceedings of the National Academy of Sciences 93, no. 23 (1996 12671 12677. (Pubitemid 26382702)
24. E. R. Berndt, I. M. Cockburn, and K. A. Grépin The Impact of Incremental Innovation in Biopharmaceuticals: Drug Utilization in Original and Supplemental Indications Pharmacoeconomics 24, supplement 2 (2006 69 83.
25. A. S. Kesselheim, M. A. Fischer, and J. Avorn Extensions of Intellectual Property Rights and Delayed Adoption of Generic Drugs: Effects on Medicaid Expenditures Health Affairs 25, no. 6 (2006 1637 1647.
26. A. B. Jaffe and J. Lerner, Innovation and its Discontents (Princeton, NJ : Princeton University Press, 2004).
27. U.S. Congressional Budget Office, How Increased Competition from Generic Drugs Has Affected Prices and Returns in the Pharmaceutical Industry, July 1998, available at http://www.cbo.gov/ftpdocs/6xx/doc655/pharm.pdf (last visited March 27, 2009).
28. H. Markel Patents Could Block the Way to a Cure New York Times, August 24, 2001 : at A19.
29. G. K. Sobolski, J.H. Barton, and E. J. Emanuel Technology Licensing: Lessons from the US Experience JAMA 294, no. 24 (2005 3137 3140. (Pubitemid 43016807)
30. A. Catlin, C. Cowan, M. Hartman, and S. Heffler National Health Spending in 2006: A Year of Change for Prescription Drugs Health Affairs 27, no. 1 (2008 14 29 K. Levit, C. Smith, C. Cowan, H. Lazenby, and A. Martin, "Inflation Spurs Health Spending in 2000," Health Affairs 21, no. 1 (2002): 172-181.
31. J. A. Vernon Simulating the Impact of Price Regulation on Pharmaceutical Innovation Pharmaceutical Development and Regulation 1, no. 1 (2003 55 65.
32. M. Goozner, The $800 Million Pill: The Truth Behind the Cost of New Drugs (Berkeley, CA : University of California Press, 2004).